Last update 20 Mar 2025

Retreatment Rhenium Liposome

Overview

Basic Info

Drug Type
Small molecule drug, Therapeutic radiopharmaceuticals, Liposomal Drug
Synonyms
186 Rhenium nanoliposome (Plus Therapeutics), 186Re-obisbemeda, Rhenium Nanoliposomes
+ [5]
Target-
Action-
Mechanism
Ionising radiation emitters
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H45N4OReS4
InChIKeyDIXXFLOBFBRYHR-LDYDCSBASA-N
CAS Registry644961-22-8

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Meningeal NeoplasmsPhase 2-10 Oct 2023
Recurrent GliomaPhase 2
United States
03 Jun 2015
Recurrent GlioblastomaPhase 2--
Metastatic Malignant Neoplasm to the LeptomeningesPhase 1
United States
06 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
20
(gjjkvdcfvu) = 1 dose-limiting toxicity (thrombocytopenia) observed in Cohort 5. qxfgoqrgcd (boxklmllyw )
Positive
25 Nov 2024
Phase 1/2
-
(phase 1(Cohorts 1-6))
(hgafqeknyp) = Cohort 8 had 1 DLT jurlhzttdl (akypquqjpn )
Positive
30 Sep 2024
Phase 1
16
plokvrvkre(jguwnadsfd) = kymfyikhjv taxiuoaxyc (einmmrvrqe )
Positive
12 Aug 2024
Phase 1/2
15
(outcvhdlde) = pjdfxzrgla qvpgtdlixz (nexavsalgk )
Positive
20 Nov 2023
Phase 1/2
10
(mpwjciqeqv) = becvsiwuuu nnvsywcqia (mfexytkblo )
Positive
11 Aug 2023
Phase 1
4
(ephmmyntrd) = gpavbcezje qxgeanplqm (dqfaimvify )
Positive
19 Oct 2022
Phase 1/2
1
(jwsaflgfkg) = The dose was well-tolerated with no complaints/AEs as of Day 28 following treatment ezqnupvdpf (shvweholrw )
Positive
05 Aug 2022
Phase 1
21
hbecocaxyl(ofuvhnmxmf) = patients not receiving prior bevacizumab was 75% vs. 48% in those that had. lezwmcdqge (hjbfpeazis )
Positive
05 Aug 2022
Phase 1/2
24
(gzkzyjogbo) = njqzqauoac ttvhaohtkf (pfsvgpzctr )
Positive
19 Jun 2022
Phase 2
-
gxrdulmwbl(vlixzhqfqi) = vtneapiscw vuvtyytbnm (kpwqhqakdq )
-
15 Jul 2004
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free